drugset / Trial / NCT05325593
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Phase 3
Active not recruiting
129 enrolled
Andalusian Public Foundation for Health Research in Seville
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase III, open-labeled, randomized and multicenter clinical trial to evaluate the superiority of romiplostim plus dexamethasone vs dexamethasone alone in patients with newly diagnosed primary immune thrombocytopenia
Timeline
- Start
- 2022-12-02
- Primary completion
- 2026-10-24
- Completion
- 2026-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Romiplostim | Peptide | 10 ug/kg | Subcutaneous |